Proficio Capital Partners LLC Makes New $148,000 Investment in Certara, Inc. (NASDAQ:CERT)

Proficio Capital Partners LLC bought a new position in Certara, Inc. (NASDAQ:CERT) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 13,856 shares of the company’s stock, valued at approximately $148,000.

A number of other large investors have also recently modified their holdings of CERT. Venturi Wealth Management LLC lifted its holdings in Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after buying an additional 2,509 shares during the period. Blue Trust Inc. raised its position in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares in the last quarter. KBC Group NV lifted its stake in shares of Certara by 64.1% in the 4th quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after purchasing an additional 3,125 shares during the period. GAMMA Investing LLC lifted its stake in shares of Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares during the period. Finally, Moloney Securities Asset Management LLC bought a new stake in shares of Certara during the fourth quarter valued at approximately $128,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

Shares of CERT stock opened at $9.91 on Friday. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -49.55, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a one year low of $9.41 and a one year high of $19.18. The company’s 50-day moving average is $12.43 and its 200 day moving average is $11.44.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CERT shares. TD Cowen started coverage on Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. William Blair reiterated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Stephens reissued an “overweight” rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays raised their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.